Cargando…
Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials
BACKGROUND: As an important antivascular endothelial growth factor monoclonal antibody, bevacizumab has been administrated for the treatment of cancer patients. Hemorrhage, one of the common adverse events of angiogenesis inhibitors, sometimes is also fatal and life-threatening. We aimed at determin...
Autores principales: | Zhu, Xiaoqiang, Tian, Xianglong, Yu, Chenyang, Hong, Jie, Fang, Jingyuan, Chen, Haoyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400309/ https://www.ncbi.nlm.nih.gov/pubmed/27559943 http://dx.doi.org/10.1097/MD.0000000000004232 |
Ejemplares similares
-
A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer
por: Zhao, Zhifei, et al.
Publicado: (2017) -
The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis
por: Zhang, Hailing, et al.
Publicado: (2021) -
Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study
por: Hosokawa, Ayumu, et al.
Publicado: (2020) -
Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021) -
Case report: Severe cholestatic jaundice associated with hyperthyroidism treated with methimazole
por: Liu, Xiaoqiang, et al.
Publicado: (2023)